Safeguarding life and longevity by empowering the brain through all stages of life stands at the core of NLS Pharmaceutic's mission. In 2015 a team of researchers, drug developers and commercial leaders shared a vision of developing safe and effective drugs to measurably improve mental and behavioral disorders. Over the years since then, the team has dedicated itself to turning its vision into reality. Worldwide, millions of people suffer from central nervous system (CNS) disorders. Over three million people across the globe are challenged by narcolepsy, an inability to regulate sleep-wake cycles. In the United States alone, 11 percent of children between four and eleven years old are distressed by a form of ADHD, creating a heavy burden on the individual, their families, and society as a whole. NLS Pharmaceutics is dedicated to helping patients worldwide access safer, better-tolerated and efficacious CNS therapies. Alex Zwyer Chief Executive Officer & Co-Founder play_arrow Latest News ConferencesAugust 5, 2021 NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference more ConferencesJuly 9, 2021 NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th more ConferencesJune 2, 2021 NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021 more ConferencesFebruary 25, 2021 NLS Pharmaceutics to Participate in Upcoming Investor Conferences more This website uses cookies for analysis. You can find exact details in our privacy policy. No thank youOk Partnerships Contact NLS Pharmaceutics AG Alter Postplatz 2 CH-6370 Stans NW Switzerland P: +41 41 618 80 00 F: +41 41 618 80 09 contact@nls-pharma.com About NLS Science News Investors About Contact Legal Privacy Policy Terms and Conditions Cookie Policy Follow us ©2021 NLS Pharmaceutics. All rights reserved.